FDA Accepts Zingo(TM) Supplemental New Drug Application To Reduce Pain Associated With Peripheral Needle Insertion Procedures In Adults
Anesiva, Inc. (Nasdaq: ANSV) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults.
More: continued here